

NEW DATA MORE MOMENTUM


The Medtronic Renal Denervation (RDN) system is proven to reduce blood pressure[†]

Data from the SPYRAL OFF MED Pivotal Trial¹


For more details, visit RenalDenervation.com

BLOOD PRESSURE CHANGE (mmHg) BASELINE TO 3 MONTHS

Renal denervation with the Symplicity Spyral™ Multi-Electrode RDN Catheter lowered BP in the SPYRAL OFF MED Pivotal clinical trial.



RDN REDUCES BLOOD PRESSURE 24 HOURS A DAY, INCLUDING DURING HIGH RISK TIME



SUPERIOR BP REDUCTIONS

compared to sham at 3 months in the absence of anti-HTN meds*

* An analysis of covariance model was used adjusting for baseline blood pressure

ZERO

device- or procedure-related adverse events through three months in the RDN treatment arm

† At three months

†† ANCOVA Adjusted

1. Böhm M, Kario K, Townsend R, et al. Catheter-based Renal Denervation in the Absence of Antihypertensive Medications: Primary Results from the SPYRAL HTN-OFF MED Pivotal Trial. The Lancet 2020; in press.

Europe

Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

UC202012078bEE © Medtronic 2020.
All rights reserved.

medtronic.eu

For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in France.

Medtronic
Further, Together